Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.130 +0.120 (+1.33%)
Streaming Delayed Price Updated: 1:50 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants
The financial landscape of 2026 has been defined by a seismic shift in capital allocation that few analysts predicted with such intensity. For the first time in over a decade, the long-dormant Russell... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
ADMA Biologics Inc (NASDAQ:ADMA) Reports Record 2025 Results Driven by ASCENIV, Provides 2026 Outlook ↗
Via Chartmill
News headline image
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Why Are Shares Of ADMA Biologics Falling Today? ↗
ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has... 
Via Benzinga
Topics Stocks
News headline image
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ADMA Biologics Addresses Misleading Short-Seller Report
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool
News headline image
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript ↗
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗
This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗
Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies. 
Via The Motley Fool
Topics Energy
News headline image
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗
Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ADMA Biologics Inc (NASDAQ:ADMA) Emerges as a Top GARP Investment Candidate ↗
ADMA Biologics exemplifies GARP investing with strong revenue & earnings growth, high profitability, and a reasonable valuation relative to its biotech peers. 
Via Chartmill
News headline image
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why ↗
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.